Author

Pal Miheller

DIFFERENTIATION BETWEEN PANCREATIC CYSTIC LESIONS USING IMAGE PROCESSING SOFTWARE ON ENDOSCOPIC-ULTRASONOGRAPHIC (EUS) IMAGES
DIFFERENTIATION BETWEEN PANCREATIC CYSTIC LESIONS USING IMAGE PROCESSING SOFTWARE ON ENDOSCOPIC-ULTRASONOGRAPHIC (EUS) IMAGES

Pal Miheller  et al.

USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY
USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY

Pal Miheller  et al.

​EFFECTIVENESS OF EXTENDED MESENTERIC EXCISION IN PREVENTING POSTOPERATIVE CROHN’S DISEASE RECURRENCE: SYSTEMATIC REVIEW AND META-ANALYSIS
​EFFECTIVENESS OF EXTENDED MESENTERIC EXCISION IN PREVENTING POSTOPERATIVE CROHN’S DISEASE RECURRENCE: SYSTEMATIC REVIEW AND META-ANALYSIS

Pal Miheller  et al.

END-TO-END ANASTOMOSIS FOLLOWING TOTAL MESORECTAL EXCISION IS NOT INFERIOR TO OTHER TYPES OF RECONSTRUCTIVE TECHNIQUES: SYSTEMATIC REVIEW AND META-ANALYSIS
END-TO-END ANASTOMOSIS FOLLOWING TOTAL MESORECTAL EXCISION IS NOT INFERIOR TO OTHER TYPES OF RECONSTRUCTIVE TECHNIQUES: SYSTEMATIC REVIEW AND META-ANALYSIS

Pal Miheller  et al.

COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL
COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL

Pal Miheller  et al.

NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY
NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY

Pal Miheller  et al.

INFLAMMATORY BOWEL DISEASE AND SARS-COV-2 PANDEMIC - THE PATIENT'S PERSPECTIVE
INFLAMMATORY BOWEL DISEASE AND SARS-COV-2 PANDEMIC - THE PATIENT'S PERSPECTIVE

Pal Miheller  et al.

USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY
USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY

Pal Miheller  et al.

DISTINCT EFFECT OF ANTI-TUMOR NECROSIS FACTOR-ALFA AND CONVENTIONAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND META-ANALYSIS
DISTINCT EFFECT OF ANTI-TUMOR NECROSIS FACTOR-ALFA AND CONVENTIONAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND META-ANALYSIS

Pal Miheller  et al.

CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY
CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY

Pal Miheller  et al.

Item 1 - 10 / 10
1